| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Surgery [D. S. M.] and Division of Surgical Immunology [R. A. F., P. E. H., R. L. S.], Catholic Medical Center, Jamaica, New York 11432
Therapeutic interrelationships among the modalities of surgery, combination chemotherapy, and immunotherapy have been documented for a spontaneous murine mammary adenocarcinoma.
The lifetime cure rates effected by surgical tumor enucleation plus the 4-compound combination, STEM (Streptonigrin, Thioguanine, Endoxan, and Mitomycin C) were significantly enhanced by the addition of a fifth chemical agent, actinomycin D (A), to the therapeutic regimen, i.e., surgery plus STEAM.
The combination chemotherapy was administered as a high-dosage, intermittent, short-term regimen to minimize host toxicity and avoid depression of the immune response of the host. Under these conditions, a further slight augmentation of lifetime cure rates was effected by administering zymosan as nonspecific immune stimulation along with the chemotherapeutic agents.
The participation of host immunity in attaining the high tumor cure rates was demonstrated by a marked reduction in cures when the immunosuppressant, cortisone, was administered concomitantly with the combination chemotherapy following surgery.
1 This research was supported by USPHS Grant CA-04497 and Grant RO 1 CA 11281-01 from the National Cancer Institute.
2 Address reprint requests to: Dr. Daniel S. Martin, Chairman, Department of Surgery, Catholic Medical Center, 88-25 153rd Street, Jamaica, N. Y. 11432.
Received 12/29/69. Accepted 3/11/70.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |